MILFORD, Mass.--(BUSINESS WIRE)--SeraCare Life Sciences, Inc. (NASDAQ: SRLS) today announced that the Company has launched a new product in its diagnostic controls and panels portfolio—the SeraCare Human Papillomavirus (HPV) Genotype Performance Panel. This panel is the first product on the market to enable testing laboratories, researchers and diagnostic manufacturers to validate their entire HPV testing system, ensuring that testing systems can differentiate between high- and low-risk HPV genotypes. In addition, the panel contains members specific for HPV type 16 and 18, strains that lead to nearly 70% of cervical cancer cases, to allow for the evaluation of newer HPV testing systems that can distinguish these two high-risk viruses. Adoption of the panel will provide users with the most complete information available to evaluate HPV test kit efficacy and to guide more informed treatment decisions.
